Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.
Intern Med · 2012
Last updated 2026-05-28Two diabetic patients on dialysis developed pancreatitis after taking incretin-based drugs—liraglutide in one case and vildagliptin in the other. Both experienced nausea, had high pancreatic enzyme levels, and showed swelling in the tail of the pancreas on CT scans. Their symptoms improved after stopping the medications, and no other clear causes of pancreatitis were found.
AI summary of the abstract below.
| Journal | Intern Med, 2012 |
|---|---|
| Citations | 18 |
| Relative citation ratio | 0.68 |
| NIH percentile | 38 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
We herein report two cases of pancreatitis associated with incretin-based therapies in end-stage renal disease (ESRD) patients undergoing dialysis. A 75-year-old woman with a history of liraglutide use and a 68-year-old man with a history of vildagliptin use both presented with nausea. They showed elevated levels of pancreatic enzymes and pancreatic tail swelling on CT. Their symptoms improved after discontinuing the drugs. In the absence of any obvious secondary causes of pancreatitis, we believe that the pancreatitis observed in these cases was associated with the incretin-based therapies. Few reports have been published on the safety and efficacy of incretin-based therapies in ESRD patients, and it remains uncertain whether the changes in the pancreas observed in the present cases are characteristic of ESRD patients.
Verbatim abstract via PubMed 23124148 ↗